The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update.
Adv Nutr
; 14(6): 1416-1435, 2023 11.
Article
em En
| MEDLINE
| ID: mdl-37619764
ABSTRACT
The importance of nicotinamide adenine dinucleotide (NAD+) in human physiology is well recognized. As the NAD+ concentration in human skin, blood, liver, muscle, and brain are thought to decrease with age, finding ways to increase NAD+ status could possibly influence the aging process and associated metabolic sequelae. Nicotinamide mononucleotide (NMN) is a precursor for NAD+ biosynthesis, and in vitro/in vivo studies have demonstrated that NMN supplementation increases NAD+ concentration and could mitigate aging-related disorders such as oxidative stress, DNA damage, neurodegeneration, and inflammatory responses. The promotion of NMN as an antiaging health supplement has gained popularity due to such findings; however, since most studies evaluating the effects of NMN have been conducted in cell or animal models, a concern remains regarding the safety and physiological effects of NMN supplementation in the human population. Nonetheless, a dozen human clinical trials with NMN supplementation are currently underway. This review summarizes the current progress of these trials and NMN/NAD+ biology to clarify the potential effects of NMN supplementation and to shed light on future study directions.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
NAD
/
Mononucleotídeo de Nicotinamida
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article